Welcome to BioSeeker Group!

Cancer Antibodies: Competitive Positioning for Success

Additional Information

Published Date Jun 3, 2008
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 261
PDF Fact Sheet View Fact Sheet for the report Cancer Antibodies: Competitive Positioning for Success in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Antibodies: Competitive Positioning for Success.

    To find out more about Cancer Antibodies: Competitive Positioning for Success, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Antibodies: Competitive Positioning for Success is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the cancer antibody field and identified 145 drug targets belonging to 253 antibodies. This report, Cancer Antibodies: Competitive Positioning for Success, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer antibody drugs.

In the report, BioSeeker reports on 147 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 253 cancer antibody drugs designed for the treatment of 42 different cancer indications. The highest degree of distinctiveness among cancer antibodies is achieved by sorting each of them according to targeted cancer indication and drug target mix. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer antibodies. No less than 165 protein-protein interactions were recognized among and between 98 of the 145 included antibody drug targets.

Why You Should Own Your Own Copy of this Report:

  • 260+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
  • A 253 cancer antibody drugs analysis, under development by 102 investigators, covering 480 developmental projects in cancer
  • 145 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other antibody drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
  • A unique drug target combination breakdown of cancer antibodies into tumor type and developmental stage
  • Unique drug-protein target interactome- and protein-protein of drug targets interactome analysis
  • Pathway profiling of cancer antibody drug targets
  • Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs?
  • Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Antibodies: Competitive Positioning for Success.
    To find out more about Cancer Antibodies: Competitive Positioning for Success, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Antibodies: Competitive Positioning for Success is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant. Learn More


The Drug Target Atlas of Apoptotic Drugs in Oncology
First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Prostate Cancer. Learn More


Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Targeted' category:


Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications. Learn More


Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More